TriSalus Life Sciences, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
TLSI$3.22-0.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share data)
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $20,439 | $8,525 |
| Accounts receivable, net | 6,558 | 5,087 |
| Inventory, net | 3,077 | 4,048 |
| Prepaid expenses | 2,170 | 3,009 |
| Total current assets | 32,244 | 20,669 |
| Property and equipment, net | 1,808 | 1,669 |
| Right-of-use assets | 861 | 1,210 |
| Other assets | 418 | 423 |
| Total assets | $35,331 | $23,971 |
| Liabilities and Stockholders’ Deficit | ||
| Current liabilities | ||
| Trade payables | $3,002 | $2,274 |
| Accrued liabilities | 8,096 | 7,355 |
| Short-term lease liabilities | 167 | 216 |
| Other current liabilities | 234 | 383 |
| Total current liabilities | 11,499 | 10,228 |
| Long-term debt | 33,046 | 22,084 |
| Revenue base redemption liability | 383 | 507 |
| Long-term lease liabilities | 1,228 | 1,329 |
| Contingent earnout liability | 10,144 | 7,401 |
| Warrant and SEPA liabilities | 12,892 | 8,316 |
| Total liabilities | 69,192 | 49,865 |
| Commitments and contingencies | ||
| Stockholders’ deficit | ||
| Preferred Stock, $0.0001 par value, 10,000,000 shares authorized at December 31, 2025 and 2024, respectively; 0 and 3,985,002 shares issued and outstanding at December 31, 2025 and 2024, respectively | — | — |
| Common stock, $0.0001 par value, 400,000,000 shares authorized at December 31, 2025 and 2024, respectively; 49,997,836 shares and 31,279,264 shares issued and outstanding at December 31, 2025 and 2024, respectively | 4 | 3 |
| Additional paid-in capital | 296,718 | 253,652 |
| Accumulated deficit | (330,583) | (279,549) |
| Total stockholders’ deficit | (33,861) | (25,894) |
| Total liabilities and stockholders’ deficit | $35,331 | $23,971 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.